Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund

Marker Therapeutics agreed to a $25 million stock purchase deal with Chicago-based institutional investor Lincoln Park Capital Fund to help advance clinical trials for some of its immunotherapy products.

Health tech company to nearly double in size with acquisition

First Republic’s demise heaps more trouble onto Boston real estate

Developer proposes senior housing in Pompano Beach

Denver looks to lease, potentially buy, another hotel for homeless shelter

New residences slated for Annandale’s Eastgate Shopping Center, setting stage for larger redevelopment

Wells Fargo puts emphasis on Raleigh area’s startup sector

Amazon targets Fairfax County big-box center for new grocery store

‘Many lives have been ruined’: Letters from Amyris investors expose personal losses, pain

Marker Therapeutics inks $25M stock purchase agreement with Lincoln Park Capital Fund

Previous Local co-working venture secures space in Doral Center

Next Reboot of former Big Surf Wave Park as Tempe industrial park moves forward

firststargroup

Kotek touts $500M Oregon housing plan at Leadership Summit

Retirement plans see boost as states mandate IRAs and tax credits lower costs

Norton Healthcare data breach affected more than 2 million people

Houston-based cell therapy company FibroBiologics files to go public

Suggested Posts

Most Admired CEO: Stephanie Stuckey saving her family’s business

BBA, Bank of America host event to help Black-owned businesses get access to capital

Aetna to replace Blue Cross NC running multibillion-dollar State Health Plan

Albuquerque land developer delivers hundreds of residential lots, talks expansion

Offices on the Move: The business (and science) of relocation

City releases St. Mary’s Strip parking study results

MENU

FirstStar Group

More Stories

Greg Marcus named EY Entrepreneur of the Year in the Midwest